{"id":2549,"date":"2018-03-01T12:06:00","date_gmt":"2018-03-01T11:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2018\/edoxaban-zur-behandlung-venoeser-thromboembolien-bei-patienten-mit-malignen-erkrankungen"},"modified":"2018-03-01T12:06:00","modified_gmt":"2018-03-01T11:06:00","slug":"edoxaban-zur-behandlung-venoeser-thromboembolien-bei-patienten-mit-malignen-erkrankungen","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2018\/edoxaban-zur-behandlung-venoeser-thromboembolien-bei-patienten-mit-malignen-erkrankungen","title":{"rendered":"Edoxaban zur Behandlung ven\u00f6ser Thromboembolien bei Patienten mit malignen Erkrankungen"},"content":{"rendered":"<p>Akute Venenthrombosen und Lungenembolien (ven\u00f6se Thromboembolie = VTE) geh\u00f6ren zu den h\u00e4ufigen Komplikationen bei Patienten mit malignen Erkrankungen (vgl. 1). Zur Behandlung einer VTE bei diesen Patienten wird in nationalen und internationalen Leitlinien f\u00fcr die initiale Therapie (5-10 Tage) und die Erhaltungstherapie (3-6 Monate) niedermolekulares Heparin (NMH) empfohlen. Im Vergleich zu Vitamin-K-Antagonisten (VKA), der bisherigen [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Akute Venenthrombosen und Lungenembolien (ven\u00f6se Thromboembolie = VTE) geh\u00f6ren zu den h\u00e4ufigen Komplikationen bei Patienten mit malignen Erkrankungen (vgl. 1). Zur Behandlung einer VTE bei diesen Patienten wird in nationalen und internationalen Leitlinien f\u00fcr die initiale Therapie (5-10 Tage) und die Erhaltungstherapie (3-6 Monate) niedermolekulares Heparin (NMH) empfohlen. Im Vergleich zu Vitamin-K-Antagonisten (VKA), der bisherigen [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[137,61,1314,1312,2068,4995,4976,69,1328,1327,226,54,51],"class_list":["post-2549","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-antikoagulanzien","tag-beinvenenthrombose","tag-direkte-orale-antikoagulanzien","tag-doak","tag-edoxaban","tag-hokusai-vte-cancer-study","tag-lungenarterienembolie","tag-lungenembolie","tag-neue-orale-antikoagulanzien","tag-noak","tag-onkologie","tag-thromboembolie","tag-thrombose"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2549","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2549"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2549\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2549"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2549"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2549"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}